Risk of thrombotic events should not exclude transgender people from receiving hormone therapy, says new guidance

Scientist researcher chemist doctor working with transparent glassware mixing liquid solution during microbiology experiment in hospital laboratory. Medical equipment on table. Medicine concept

The negative mental and physical effects of withholding gender-affirming hormone therapy (GAHT) from transgender people may outweigh the risk of GAHT-associated venous thromboembolism (VTE), underscoring the need for a thorough upfront discussion by healthcare provider and patient, according to a study led by investigators from Massachusetts General Hospital, other Mass General Brigham hospitals, and transgender health experts from across the country.

Stemming the rising tide of firearm violence using a comprehensive public health approach

Previous article

GPs left psychologically distressed and overwhelmed by pressures of the pandemic, new study finds

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations